SLN - Spark Newswire

5 minute read

76 Biggest Movers From Yesterday: Ocean Bio-Chem, Athira Pharma And More

June 23, 4:25 AM

Gainers Ocean Bio-Chem, Inc. (NASDAQ: OBCI) shares climbed 117.2% to close at $12.86 on Wednesday after the company announced it will be acquired by OneWater Marine for $13.08 per share in cash.

ADSE

8 minute read

Stocks That Hit 52-Week Lows On Thursday

By Benzinga Insights

June 9, 1:26 PM

On Thursday, 126 companies set new 52-week lows.

AHI

6 minute read

88 Biggest Movers From Yesterday

By Lisa Levin

May 26, 5:08 AM

Gainers The Very Good Food Company Inc. (NASDAQ: VGFC) shares jumped 118.2% to close at $0.2950 on Wednesday as the company announced it increased retail distribution across Canada with Loblaw Companies.

ADXN

57 minute read

Stocks That Hit 52-Week Lows On Friday

By Benzinga Insights

May 6, 12:06 PM

On Friday, 1043 companies hit new 52-week lows.

AAOI

3 minute read

12 Health Care Stocks Moving In Thursday’s Intraday Session

By Benzinga Insights

April 28, 3:18 PM

COSM

4 minute read

62 Biggest Movers From Yesterday

By Lisa Levin

April 28, 4:17 AM

Gainers Tenon Medical, Inc. (NASDAQ: TNON) rose 350% to clsoe at $22.50 on Wednesday after the company priced its IPO at $5.00 per share.

AFIB

44 minute read

Stocks That Hit 52-Week Lows On Wednesday

By Benzinga Insights

April 27, 2:41 PM

Wednesday's session saw 784 companies set new 52-week lows.

AADI

1 minute read

Chardan Capital Initiates Coverage On Silence Therapeutics with Buy Rating, Announces Price Target of $33

By Benzinga Newsdesk

March 31, 8:53 AM

Chardan Capital analyst Keay Nakae initiates coverage on Silence Therapeutics (NASDAQ:SLN) with a Buy rating and announces Price Target of $33.

SLN

1 minute read

Silence Therapeutics And Mallinckrodt Announce Submission Of Clinical Trial Application For SLN501; Silence To Receive $3M Milestone Payment

By Bill Haddad

March 23, 7:21 AM

Silence to receive $3 million research milestone payment from Mallinckrodt Phase 1 study expected to begin in the first half of 2022 LONDON & DUBLIN--(BUSINESS WIRE)-- Silence Therapeutics plc (NASDAQ:SLN), a

MNKKQ